v3.26.1
Summary of Significant Accounting Policies (Details Narrative)
3 Months Ended 12 Months Ended
May 22, 2023
$ / shares
Mar. 31, 2026
USD ($)
Segment
$ / shares
shares
Mar. 31, 2025
USD ($)
shares
Mar. 31, 2024
USD ($)
Dec. 31, 2025
USD ($)
$ / shares
shares
Nov. 03, 2025
$ / shares
shares
Nov. 02, 2025
shares
Dec. 31, 2024
USD ($)
Sep. 05, 2023
$ / shares
shares
Sep. 04, 2023
shares
AccountingPoliciesLineItems [Line Items]                    
Reverse stock split 1-for-5                  
Common stock par value | $ / shares $ 0.001 $ 0.001     $ 0.001       $ 0.001  
Common stock authorized | shares   5,000,000,000     5,000,000,000       250,000,000 3,000,000
Goodwill impairment loss   $ 218,606              
Provision for doubtful accounts   121 287   $ (109)          
Inventory write down   2,354 3,681              
Other income expenses net   790,000                
Research and development expense   390              
Income Tax Expense (Benefit)   62,260              
Accumulated undistributed loss   21,700,000     21,700,000          
Unrecognized tax benefits            
Unrecognized tax benefits affect the effective tax rate                
Penalties and interest expense   0     0          
Income tax penalties and interest              
Number of reportable segment | Segment   1                
Contract liabilities   $ 89,147     58,786          
Accounts Receivable [Member] | One Customer [Member] | Customer Concentration Risk [Member]                    
AccountingPoliciesLineItems [Line Items]                    
Concentration risk percentage     14.00%              
Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]                    
AccountingPoliciesLineItems [Line Items]                    
Advances to suppliers   89,387 $ 159,050              
Accounts payable   $ 0 $ 0              
Restricted Stock [Member]                    
AccountingPoliciesLineItems [Line Items]                    
Anti-dilutive shares exercisable | shares   0 3,000              
Warrant [Member]                    
AccountingPoliciesLineItems [Line Items]                    
Anti-dilutive shares exercisable | shares   1,494,588 245,192              
Continuing Operations [Member]                    
AccountingPoliciesLineItems [Line Items]                    
Research and development expense   $ 0 $ 390              
Shipping and handling (credits) costs   0 2,033              
Advertising expense   $ 101,986 $ 15,380              
Continuing Operations [Member] | Revenue Benchmark [Member] | One Customer [Member] | Customer Concentration Risk [Member]                    
AccountingPoliciesLineItems [Line Items]                    
Concentration risk percentage   10.00% 10.00%              
Continuing Operations [Member] | Cost of Goods and Service Benchmark [Member] | Major Vendor One [Member] | Supplier Concentration Risk [Member]                    
AccountingPoliciesLineItems [Line Items]                    
Concentration risk percentage   16.00% 11.00%              
Preamble Capital LLC [Member]                    
AccountingPoliciesLineItems [Line Items]                    
Equity method investments   $ 25,860,000     22,820,000          
Other income expenses net   790,000                
Investments fair value   $ 26,950,000     $ 23,100,000          
Computer Software [Member]                    
AccountingPoliciesLineItems [Line Items]                    
Estimated useful life   5 years                
Board of Directors Chairman [Member]                    
AccountingPoliciesLineItems [Line Items]                    
Common stock par value | $ / shares           $ 0.001        
Common stock authorized | shares           5,000,000,000 250,000,000